Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China

Table 1 Characteristics of patients with advanced hepatocellular carcinoma treated with lenvatinib

	All (n = 54)	HBV-related HCC (n = 40)
Age, yr	58.94 ± 12.10	57.49 ± 12.03
Gender (male:female)	46:8	35:5
Height, cm	172.04 ± 7.65	171.72 ± 7.24
Weight, kg	70.47 ± 13.72	69.21 ± 12.35
Etiology (HBV:HCV:Others)	40:5:9	40
Total bilirubin, mg/dL	29.81 ± 31.35	32.40 ± 33.17
Albumin, g/dL	38.53 ± 5.64	38.73 ± 5.01
Prothrombin time, positive, %	14 (26%)	10 (25%)
Extrahepatic spread	18 (33.3%)	12 (30%)
Lymphatic metastasis	33 (61%)	28 (70%)
Liver occupation (< 50%: > 50%)	38:15	27:13
Portal vein thrombus	21 (39%)	16 (40%)
Baseline AFP (ng/mL)(≥ 200: < 200)	32:22	22:18
Native: Recurrence	28:26	19:21
History of treatment (TACE: RFA: Targeted therapy)	37:21:17	29:14:14
History of Radiotherapy	11 (20%)	7 (18%)
Initial dose of LEN (8 mg: 12 mg)	26:28	21:19
Diagnostic method (Image: Pathology)	25:29	21:19
Size of target lesion, cm	6.93 ± 4.75	7.25 ± 4.36

AFP: α-fetoprotein; HBV: Hepatitis B virus; EHS: Extrahepatic spread; HCV: Hepatitis C virus; LEN: Lenvatinib; TACE: Transcatheter arterial chemoembolization; RFA: Radiofrequency ablation.